Ab Science SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
AB Science proposes allocation of FY 2013 result and share repurchase program
AB Science SA:To propose to annual general meeting on June 27 that loss made in FY 2013 (14,254,907 euros) be allocated to retained earnings account.Says that no dividend has been paid for last three fiscal years.To propose terms of share repurchase program to annual general meeting.Program would authorize repurchase of up to 10 pct of capital.Maximum price per share 36 euros.Total maximum that could be spent 25 million euros.Authorization valid for 18 months.
Latest Developments for Ab Science SA
- AB Science DSMB recommends the continuation of phase 3 study of masitinib in progressive forms of multiple sclerosis
- AB Science says DSMB recommends continuation of its phase 3 study of Masitinib in mastocytosis
- AB Science announces publication of results from randomized phase 2 study of masitinib
- AB Science SA leaves SBF 120 Index and share price falls sharply-DJ
Latest Key Developments in Pharmaceuticals
- Intellipharmaceutics International Inc reports positive results from a Series of Phase I Clinical Trials of Regabatin XR (Pregabalin Extended-Release)
- Tetraphase Pharmaceuticals Inc announces closing of public offering of common stock
- Actavis PLC signs option to acquire Rhythm
- Relypsa submits New Drug Application to U.S. FDA seeking approval for Patiromer for Oral Suspension to Treat Hyperkalemia
- Share this
- Digg this